Antimicrobial

Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings

- VCN-01 expanded mPDAC data from VIRAGE Phase 2b trial to be presented at ESMO 2025 - - SYN-004 Interim…

2 months ago

Immuron Q1 FY26 YoY growth

Sales Highlights (unaudited): Global•Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp)   Australia•Q1 sales AUD$1.6 million up 52% on…

2 months ago

Novo Nordisk Foundation commits up to DKK 200 million to fund new platform to strengthen global defence against future pandemics

COPENHAGEN, Denmark, Oct. 13, 2025 /PRNewswire/ -- The AI-powered Global Pathogen Analysis Platform aims to strengthen the pandemic preparedness globally.…

2 months ago

Genvor Restores Trading Status and Expands Global Collaborative Research Network

Woodland, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCID: GNVR), a pioneer in AI-accelerated peptide technology for sustainable…

2 months ago

Reolite Secures Historic U.S. EPA Registration and Earns Recognition from MIT Lincoln Laboratory, Paving the Way for Entry into $2.7 Trillion Apparel and Plastics Markets

LOS ANGELES, Oct. 6, 2025 /PRNewswire/ -- Robin K. International Inc. (DBA Reolite, Chairman Billy Kang), headquartered in Los Angeles,…

2 months ago

Nutromics unveils world-first real-time in vivo multiplexing data at IATDMCT

MELBOURNE, Australia, Oct. 2, 2025 /PRNewswire/ -- Diagnostics company Nutromics has presented the world's first real-time, continuous data on two…

3 months ago

Sanara MedTech to Report Third Quarter 2025 Financial Results on November 12, 2025

FORT WORTH, TX, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical…

3 months ago

AUA Guidelines Recognize NGS in Recurrent UTI Care, Signaling Progress

NGS use is validated in 2025 American Urological Association guideline update, marking an important step towards more accurate and rapid…

3 months ago

CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO

- Enrollment Completed in Ongoing Phase III ReSPECT Study in Prophylaxis of Fungal Infections in Adult Patients Undergoing Allogeneic Blood…

3 months ago

Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam

- Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of…

3 months ago